Discovery of beta-lactamase CMY-10 inhibitors for combination therapy against multi-drug resistant Enterobacteriaceae.
β-lactam antibiotics are the most widely used antimicrobial agents since the discovery of benzylpenicillin in the 1920s. However, the emergence of multi-drug resistant (MDR) Enterobacteriaceae has become a significant global health challenge. These bacteria have developed resistance to multiple classes of antibiotics, including β-lactamase inhibitors. In this study, we aimed to discover beta-lactamase CMY-10 inhibitors for combination therapy against MDR clinical isolates that have been found resistant against last-line antibiotics.